We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

244 hedge funds and large institutions have $1.56B invested in Supernus Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 87 increasing their positions, 80 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $352K

2.65% more ownership

Funds ownership: 103.59% → 106.23% (+2.6%)

9% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 80

6% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 34

2% less funds holding

Funds holding: 250 → 244 (-6)

19% less capital invested

Capital invested by funds: $1.93B → $1.56B (-$370M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
244
Holders Change
-6
Holders Change %
-2.4%
% of All Funds
3.52%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
32
Increased
87
Reduced
80
Closed
34
Calls
$1.29M
Puts
$352K
Net Calls
+$939K
Net Calls Change
-$275K

Top Buyers

1
AC
Armistice Capital
New York
+$49.3M
2
Pacer Advisors
Pacer Advisors
Pennsylvania
+$39.1M
3
American Century Companies
American Century Companies
Missouri
+$11.4M
4
Renaissance Technologies
Renaissance Technologies
New York
+$10.2M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$8.98M

Top Sellers

1
WP
Woodline Partners
California
-$44M
2
CAM
Congress Asset Management
Massachusetts
-$29.7M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$12.9M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$11.5M
5
CWM
Congress Wealth Management
Massachusetts
-$6.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$13.4M +$11.4M +394,728 +369%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$11.4M +$70.3K +2,427 +0.6%
Bank of America
28
Bank of America
North Carolina
$10.8M +$1.3M +45,002 +12%
TCM
29
Tributary Capital Management
Nebraska
$9.23M +$8.2K +283 +0.1%
SEI Investments
30
SEI Investments
Pennsylvania
$9.03M +$205K +7,078 +2%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$7.78M +$4.65M +160,431 +123%
MOACM
32
Mutual of America Capital Management
New York
$7.45M -$1.23M -42,484 -13%
Principal Financial Group
33
Principal Financial Group
Iowa
$7.25M -$381K -13,151 -5%
SI
34
Scout Investments
Missouri
$6.48M -$672K -23,196 -9%
Norges Bank
35
Norges Bank
Norway
$5.59M -$679K -23,410 -10%
PCM
36
Peregrine Capital Management
Minnesota
$5.41M -$20.3K -699 -0.3%
TAM
37
Third Avenue Management
New York
$5.06M +$852K +29,401 +18%
JP Morgan Chase
38
JP Morgan Chase
New York
$4.82M -$488K -16,836 -9%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$4.82M +$168K +5,813 +3%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$4.61M +$4.99M +172,266 New
Millennium Management
41
Millennium Management
New York
$4.32M +$3.73M +128,743 +395%
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
$4.28M +$4.36M +150,569 +1,568%
Legal & General Group
43
Legal & General Group
United Kingdom
$4.09M -$33.8K -1,165 -0.8%
Citadel Advisors
44
Citadel Advisors
Florida
$3.82M +$1.61M +55,638 +64%
DZ Bank
45
DZ Bank
Germany
$3.81M -$905K -31,232 -18%
CS
46
Candriam SCA
Luxembourg
$3.8M +$4.11M +141,889 New
Point72 Asset Management
47
Point72 Asset Management
Connecticut
$3.65M +$247K +8,521 +7%
N
48
Nuveen
North Carolina
$3.56M -$2.72M -93,808 -41%
STB
49
S&T Bank
Pennsylvania
$3.41M -$1.39M -47,928 -27%
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
$3.29M +$3.16M +109,088 +1,508%
1
2
3 4 5

SUPN Hedge Fund Activity: Q2 2024 in Review

244 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2024, worth a combined $1.56B — down 19% from $1.93B a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of SUPN and 32 opened new positions — a net loss of 2 holders — while 80 trimmed existing stakes and 87 added.

The largest buyer was Armistice Capital, adding an estimated $49.3M. The largest seller was Woodline Partners, exiting entirely with an estimated $44M sold.

  • 244 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2024, down from 250 in Q1 2024.
  • Funds reported $1.56B of Supernus Pharmaceuticals stock for Q2 2024, down 19% quarter-over-quarter.
  • 32 funds opened new Supernus Pharmaceuticals positions in Q2 2024 and 34 closed out, a net change of -2 holders.
  • The largest Supernus Pharmaceuticals buyer in Q2 2024 was Armistice Capital, an estimated $49.3M added.
  • The largest Supernus Pharmaceuticals seller in Q2 2024 was Woodline Partners, an estimated $44M sold.

Based on aggregated 13F filings for Q2 2024.